Nifty
Sensex
:
:
16352.45
54884.66
182.30 (1.13%)
632.13 (1.17%)

Pharmaceuticals & Drugs - Global

Rating :
39/99

BSE: 532531 | NSE: STAR

321.70
26-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  308.00
  •  326.00
  •  306.30
  •  306.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2377592
  •  7565.26
  •  847.80
  •  263.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,890.33
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,813.96
  • 0.78%
  • 1.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.60%
  • 0.00%
  • 21.82%
  • FII
  • DII
  • Others
  • 19.66%
  • 17.34%
  • 10.58%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -2.82
  • 2.18

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 3.93
  • 16.14

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -1.72
  • -0.37

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.43
  • 11.37
  • 11.37

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.95
  • 1.96
  • 1.85

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.30
  • 14.61
  • 14.86

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
866.02
908.49
-4.67%
794.39
832.02
-4.52%
721.47
793.56
-9.08%
688.37
781.80
-11.95%
Expenses
823.85
751.26
9.66%
792.86
672.62
17.88%
735.04
636.35
15.51%
743.72
630.79
17.90%
EBITDA
42.16
157.24
-73.19%
1.53
159.41
-99.04%
-13.57
157.21
-
-55.35
151.01
-
EBIDTM
4.87%
17.31%
0.19%
19.16%
-1.88%
19.81%
-8.04%
19.32%
Other Income
86.06
13.05
559.46%
10.19
14.40
-29.24%
22.21
17.75
25.13%
18.65
16.20
15.12%
Interest
49.48
41.61
18.91%
42.25
34.68
21.83%
43.55
36.87
18.12%
41.45
36.91
12.30%
Depreciation
60.68
51.86
17.01%
60.90
52.51
15.98%
56.56
52.79
7.14%
54.88
49.13
11.70%
PBT
-58.88
75.89
-
-106.86
72.85
-
-151.37
98.44
-
-224.58
126.08
-
Tax
-131.48
11.49
-
-4.48
10.77
-
-6.76
6.10
-
-35.54
3.28
-
PAT
72.60
64.40
12.73%
-102.38
62.07
-
-144.61
92.34
-
-189.04
122.80
-
PATM
8.38%
7.09%
-12.89%
7.46%
-20.04%
11.64%
-27.46%
15.71%
EPS
3.25
5.14
-36.77%
-13.55
4.22
-
-18.11
9.03
-
-22.87
11.56
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Net Sales
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
Net Sales Growth
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
39.43%
-62.28%
 
Cost Of Goods Sold
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
Gross Profit
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
GP Margin
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
Total Expenditure
3,095.47
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
Power & Fuel Cost
-
64.58
64.49
54.39
51.33
33.87
77.18
16.02
18.56
12.84
54.24
% Of Sales
-
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
Employee Cost
-
550.15
442.56
329.44
434.05
419.16
357.69
172.06
157.18
120.30
302.74
% Of Sales
-
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
Manufacturing Exp.
-
237.94
210.79
150.98
115.97
137.47
119.23
41.37
35.76
44.43
89.60
% Of Sales
-
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
General & Admin Exp.
-
191.73
191.89
150.10
194.38
172.63
198.71
86.25
66.37
58.16
182.12
% Of Sales
-
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
Selling & Distn. Exp.
-
223.22
137.07
111.22
208.85
161.12
129.57
61.37
66.67
39.94
116.07
% Of Sales
-
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
Miscellaneous Exp.
-
88.65
301.61
930.33
725.25
1,103.88
96.95
29.44
58.33
93.69
116.07
% Of Sales
-
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
EBITDA
-25.23
626.81
510.22
296.68
235.71
516.92
380.57
228.85
223.42
100.58
490.68
EBITDA Margin
-0.82%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
Other Income
137.11
73.39
66.70
322.90
920.64
398.08
102.37
38.57
60.23
34.20
31.67
Interest
176.73
150.06
155.72
79.29
196.24
183.10
168.17
47.44
108.88
79.45
194.83
Depreciation
233.02
206.29
187.79
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
PBT
-541.69
343.85
233.42
368.44
766.17
533.20
183.50
155.95
118.30
24.48
223.22
Tax
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
40.86
11.15
38.68
Tax Rate
32.91%
8.17%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
PAT
-363.43
366.26
143.62
370.31
681.31
399.38
113.21
1.57
50.89
712.39
224.48
PAT before Minority Interest
-349.39
355.55
137.82
375.57
701.18
445.58
99.68
0.98
50.89
713.44
234.01
Minority Interest
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
PAT Margin
-11.84%
11.05%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
PAT Growth
-206.39%
155.02%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
 
EPS
-40.47
40.79
15.99
41.24
75.87
44.47
12.61
0.17
5.67
79.33
25.00

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Shareholder's Funds
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
Share Capital
89.68
89.56
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
Total Reserves
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
Non-Current Liabilities
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
Secured Loans
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
Unsecured Loans
9.15
2.12
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
Long Term Provisions
246.50
63.95
52.24
16.55
25.19
14.45
6.02
16.56
57.25
66.19
Current Liabilities
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
Trade Payables
1,178.62
797.75
888.99
712.07
774.09
775.40
234.41
262.31
463.08
585.04
Other Current Liabilities
376.58
354.49
248.12
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
Short Term Borrowings
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
Short Term Provisions
159.31
163.84
186.11
112.86
116.73
68.19
80.03
93.23
82.66
152.24
Total Liabilities
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
Net Block
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
Gross Block
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
Accumulated Depreciation
690.15
508.53
478.92
326.03
277.09
146.75
379.19
352.80
497.57
457.19
Non Current Assets
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
Capital Work in Progress
447.37
412.95
453.03
620.29
780.18
814.88
171.17
99.47
241.44
285.03
Non Current Investment
666.23
503.24
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
Long Term Loans & Adv.
185.80
210.82
223.69
197.22
222.56
201.83
96.72
90.40
118.75
229.99
Other Non Current Assets
549.04
428.19
16.86
30.72
15.62
22.62
1.91
1.45
6.96
8.67
Current Assets
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
Current Investments
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
Inventories
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
175.99
442.33
479.93
Sundry Debtors
1,106.86
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
Cash & Bank
179.76
237.10
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
Other Current Assets
230.49
83.57
136.87
138.84
454.09
343.44
123.64
136.26
319.58
347.17
Short Term Loans & Adv.
132.27
218.24
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
Net Current Assets
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
Total Assets
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Cash From Operating Activity
481.44
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
PBT
289.38
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
Adjustment
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
Changes in Working Capital
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
Cash after chg. in Working capital
324.64
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
Net Fixed Assets
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
Net Investments
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
Others
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
Cash from Financing Activity
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
Net Cash Inflow / Outflow
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
Opening Cash & Equivalents
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
Closing Cash & Equivalent
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Book Value (Rs.)
309.09
281.55
294.94
274.26
306.41
296.83
191.91
168.99
343.78
233.49
ROA
5.57%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
ROE
13.43%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
ROCE
11.47%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
Fixed Asset Turnover
2.04
1.50
1.17
1.04
1.27
1.47
1.21
0.61
0.27
0.82
Receivable days
67.97
70.88
79.95
102.49
96.77
90.73
114.71
114.80
193.43
65.68
Inventory Days
66.13
61.20
61.00
70.11
64.20
52.34
58.37
83.78
174.61
56.40
Payable days
270.63
138.58
146.59
116.23
117.33
75.51
76.81
112.69
253.28
92.58
Cash Conversion Cycle
-136.53
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
114.76
29.50
Total Debt/Equity
0.76
0.78
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
Interest Cover
3.58
2.00
5.92
4.68
3.71
1.85
4.13
1.84
10.12
2.40

News Update:


  • Strides Pharma Scien - Quarterly Results
    24th May 2022, 21:31 PM

    Read More
  • Strides Pharma Science inks sub-license agreement with MPP
    21st Mar 2022, 09:40 AM

    Branded as Kovidax, Strides’ generic version of the Pfizer oral treatment will be launched in 95 markets as part of the sub-licensing agreement with MPP

    Read More
  • Strides Pharma Science’s arm gets USFDA approval for Colchicine Tablets
    11th Mar 2022, 10:47 AM

    The company has 271 cumulative ANDA filings with USFDA of which 245 ANDAs have been approved and 26 are pending approval

    Read More
  • Strides Pharma Science’s arm gets USFDA nod for amantadine hydrochloride softgel capsules
    21st Feb 2022, 09:10 AM

    The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.